NRG Therapeutics Raises £16M in Series A Funding

NRG Therapeutics, a UK-based neuroscience company, has raised £16 million in Series A funding led by Omega Funds, with participation from Brandon Capital and Parkinson’s Virtual Biotech. The company plans to use the funds to advance its first-in-class brain-penetrant small molecules through IND-enabling studies. NRG Therapeutics is applying science in the field of mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and ALS. 

NRG Therapeutics Secures £16 Million Series A Funding to Advance Neurodegenerative Disease Therapies

NRG Therapeutics is a Stevenage, UK-based neuroscience company developing disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and ALS (also known as motor neurone disease or MND). Its pre-clinical pipeline includes small molecule assets which inhibit the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action. The company is targeting a novel pathological mechanism in ALS, through which the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING, that was identified by its collaborator Professor Seth Masters, at Australia’s WEHI (Walter and Eliza Hall Institute of Medical Research).

A neuroscience company developing disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and ALS.

3 years ago

NRG Therapeutics Secures £16 Million Series A Funding to Advance Neurodegenerative Disease Therapies

ProblemHealthcare

Solution

Covered on